PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Rhea-AI Summary

PolyPid Ltd. (PYPD) has announced a conference call and webcast scheduled for Monday, June 9, 2025, at 8:30 AM ET to discuss topline results from their SHIELD II Phase 3 trial. The trial evaluates D-PLEX100, their candidate for preventing surgical site infections in abdominal colorectal surgery patients. The company, which focuses on improving surgical outcomes, recommends participants register at least 5 minutes before the call's start time. The event will be accessible via both conference call and webcast formats.

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX₁₀₀ for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call.

Conference Call Dial-In & Webcast Information:

Date:	Monday, June 9, 2025
Time:	8:30 AM Eastern Time
Conference Call:	https://register-conf.media-server.com/register/BIb5bb85aa1ffc4940b78f7191b278ca77
Webcast:	https://edge.media-server.com/mmc/p/k6n5hrft

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

When will PolyPid (PYPD) announce SHIELD II Phase 3 trial results?

PolyPid will announce SHIELD II Phase 3 trial results on Monday, June 9, 2025, at 8:30 AM Eastern Time.

What is the purpose of PolyPid's SHIELD II Phase 3 trial?

The SHIELD II Phase 3 trial evaluates D-PLEX100 for preventing surgical site infections in patients undergoing abdominal colorectal surgery.

How can investors access PolyPid's SHIELD II trial results conference call?

Investors can access the conference call by registering through the provided link, with registration recommended at least 5 minutes before the 8:30 AM ET start time.

What is D-PLEX100 being developed for by PolyPid?

D-PLEX100 is being developed for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery.